ImmuPharma Statistics

Total Valuation

ImmuPharma has a market cap or net worth of GBP 12.72 million. The enterprise value is 11.64 million.

Market Cap	12.72M
Enterprise Value	11.64M

Important Dates

The next estimated earnings date is Thursday, April 24, 2025.

Earnings Date	Apr 24, 2025
Ex-Dividend Date	n/a

Share Statistics

ImmuPharma has 416.44 million shares outstanding. The number of shares has increased by 23.36% in one year.

Current Share Class	n/a
Shares Outstanding	416.44M
Shares Change (YoY)	+23.36%
Shares Change (QoQ)	+6.61%
Owned by Insiders (%)	0.90%
Owned by Institutions (%)	61.11%
Float	295.45M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	4.73
P/TBV Ratio	5.70
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.73
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.60

Current Ratio	1.60
Quick Ratio	1.30
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-601.38

Financial Efficiency

Return on equity (ROE) is -111.20% and return on invested capital (ROIC) is -71.38%.

Return on Equity (ROE)	-111.20%
Return on Assets (ROA)	-43.00%
Return on Invested Capital (ROIC)	-71.38%
Return on Capital Employed (ROCE)	-93.97%
Revenue Per Employee	-13,992
Profits Per Employee	-492,456
Employee Count	5
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +38.08% in the last 52 weeks. The beta is 2.58, so ImmuPharma's price volatility has been higher than the market average.

Beta (5Y)	2.58
52-Week Price Change	+38.08%
50-Day Moving Average	3.93
200-Day Moving Average	2.29
Relative Strength Index (RSI)	37.41
Average Volume (20 Days)	3,298,739

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ImmuPharma had revenue of GBP -69,959 and -2.46 million in losses. Loss per share was -0.01.

Revenue	-69,959
Gross Profit	-69,959
Operating Income	-2.53M
Pretax Income	-2.88M
Net Income	-2.46M
EBITDA	-2.56M
EBIT	-2.53M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 1.08 million in cash and n/a in debt, giving a net cash position of 1.08 million or 0.00 per share.

Cash & Cash Equivalents	1.08M
Total Debt	n/a
Net Cash	1.08M
Net Cash Per Share	0.00
Equity (Book Value)	2.69M
Book Value Per Share	0.01
Working Capital	819,076

Full Balance Sheet

Cash Flow

Operating Cash Flow	-1.59M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	3,614.72%
Pretax Margin	4,111.85%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ImmuPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.36%
Shareholder Yield	-23.36%
Earnings Yield	-19.35%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ImmuPharma has an Altman Z-Score of -20.01. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-20.01
Piotroski F-Score	n/a